Author: John A. Wagner, MD, PhD on March 26, 2020
As the COVID-19 pandemic takes the world by storm, the search for potential therapeutics ramps up. As of March 26, 2020, COVID-19 has plagued the world with more than 480,000 confirmed infections and 22,000 deaths. The role for therapeutics could be crucial in stemming morbidity and mortality due to the pandemic, particularly before a vaccine is available. Rayner et al. provide a commentary in Clinical and Translational Science (CTS) on insights from core clinical pharmacology and translational medicine principles, like dose-finding and characterization of exposure-response, which remain pivotal for beating back the COVID-19 scourge.
Drug repurposing and other research has rapidly led to experimental usage and new clinical trials in COVID-19, but the urgent needs of the pandemic should not overshadow rigorous translational and clinical pharmacology research standards. The health of the world is on the line. Rayner et al.’s commentary formulates four key insights relevant to optimizing COVID-19 candidate therapeutics by analyzing research to optimize anti-infective therapy in settings where the availability of quality and timely data is limited with particular focus on influenza, including experiences from H5N1 and pH1N1 outbreaks.
The ASCPT family of journals, including CTS, Clinical Pharmacology & Therapeutics, and CPT: Pharmacometrics & Systems Pharmacology, expects to leverage the collective translational and clinical pharmacology expertise of the Society and will be engaged in swift peer review of manuscripts related to COVID-19. If you are involved in this crucial fight, consider CTS, CPT, or PSP for your research. The editorial teams of all three journals welcome original COVID-19 contributions spanning the entire spectrum from discovery to implementation.
The comment feature is locked by administrator.